Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Gains from Sales and Divestitures (2016 - 2018)

Historic Gains from Sales and Divestitures for Amicus Therapeutics (FOLD) over the last 3 years, with Q1 2018 value amounting to $353442.0.

  • Amicus Therapeutics' Gains from Sales and Divestitures rose 742004.26% to $353442.0 in Q1 2018 from the same period last year, while for Mar 2018 it was $353442.0, marking a year-over-year increase of 742004.26%. This contributed to the annual value of $318200.0 for FY2017, which is 1287.69% up from last year.
  • As of Q1 2018, Amicus Therapeutics' Gains from Sales and Divestitures stood at $353442.0, which was up 742004.26% from $318200.0 recorded in Q4 2017.
  • Amicus Therapeutics' 5-year Gains from Sales and Divestitures high stood at $353442.0 for Q1 2018, and its period low was $4700.0 during Q1 2017.
  • Its 3-year average for Gains from Sales and Divestitures is $224508.4, with a median of $210911.0 in 2017.
  • Per our database at Business Quant, Amicus Therapeutics' Gains from Sales and Divestitures soared by 582.59% in 2017 and then soared by 742004.26% in 2018.
  • Quarter analysis of 3 years shows Amicus Therapeutics' Gains from Sales and Divestitures stood at $281900.0 in 2016, then rose by 12.88% to $318200.0 in 2017, then grew by 11.08% to $353442.0 in 2018.
  • Its last three reported values are $353442.0 in Q1 2018, $318200.0 for Q4 2017, and $210911.0 during Q3 2017.